HealthInvest April 2025

Morgans and IR Department, in partnership with Stockhead, are pleased to present the first HealthInvest event for 2025 on Wednesday, 2 April, 2025.

After the success of our inaugural event, and with strong investor interest driving momentum in the healthcare sector, HealthInvest returns to showcase some of Australia’s leading and emerging health and life sciences companies to an audience of professional and retail investors.

This event provides investors with a unique opportunity to hear directly from key industry leaders, followed by networking over drinks and canapés.

Presenting companies and speakers include:

• EMVision Medical Devices Limited (ASX: EMV) – Scott Kirkland, CEO and Managing Director
• Orthocell Ltd (ASX: OCC) – Paul Anderson, CEO and Managing Director
• Microba Life Sciences Limited (ASX: MAP) – Dr Luke Reid, Chief Executive Officer
• Lumos Diagnostics Holdings Ltd (ASX: LDX) – Doug Ward, CEO and Managing Director
• Dimerix Ltd (ASX: DXB) – Nina Webster, CEO and Managing Director

Join us as we explore the latest innovations shaping the future of healthcare and life sciences investment.
____________________________________________________________________

Scott Kirkland, CEO and Managing Director, EMVision Medical Devices

Scott is the co-founder of EMVision Medical Devices Ltd (ASX:EMV). Scott has held several senior sales positions, including Head of Client Sales at Quantcast, a US-based technology company, prior to establishing EMVision as a leader in innovative neurodiagnostic technology. Scott is a member of the Australian Institute of Company Directors. 

Paul Anderson, CEO and Managing Director, Orthocell

Paul has over 20 years’ experience in the medical device and cellular therapeutic fields with expertise in bridging the gap between research and clinical practice in the development of emerging medical technologies. This encompasses applying the regulatory framework to the product, rebating pathways, marketing, sales, developing key option leader relationships, strategic and financial planning. Paul has a strong track record with his previous board position with Verigen Australia Pty Ltd, a human cell therapies company. 

Dr Luke Reid, Chief Executive Officer, Microba Life Sciences

Dr Luke Reid is an experienced research and technology commercialisation executive. His deep knowledge in the biotechnology sector has underpinned Microba’s growth into a global biotech company delivering on its mission to improve human health with precision microbiome science. Dr Reid’s expertise in translational research, technology commercialisation, commercial partnerships, licensing and intellectual property management uniquely places him to lead Microba as Chief Executive Officer. Previously, Dr Reid was Associate Director at UniQuest Pty Ltd, one of the global leaders in commercialisation of university technology. Prior to UniQuest, Dr Reid held roles working with the world’s leading developer of advanced plant genetics, Dupont Pioneer, and the world leader in bioinnovation of enzymes, proteins and microorganisms, Novozymes. Dr Reid holds a PhD in molecular biology from The University of Adelaide and a Bachelor of Science (Biotechnology (Hons)) from Flinders University.

Doug Ward, CEO and Managing Director, Lumos Diagnostics

Doug Ward has more than 30 years of medical device and diagnostics experience at notable global healthcare companies including Roche, GE, Siemens, Bayer, Chiron and Hologic. Mr. Ward was named CEO of Lumos Diagnostics in June 2022 and is leveraging his industry experience and empowering leadership approach to guide Lumos Diagnostics through an exciting time of unlimited potential growth. During his career, Doug has held executive positions where he developed and implemented novel business strategies and introduced transformational products to the practice of medicine. Prior to joining Lumos, he served as Vice President, Strategy and Business Development at Hologic where he led a global team responsible for fostering innovation in women's healthcare to improve clinical results. Mr. Ward also served as the CEO of Personal Genome Diagnostics (PGDx) where he led the organisation's transformation from a clinical laboratory testing service into a fully functional molecular invitro diagnostics (IVD) company. With a deep understanding of the life sciences ecosystem, Doug excels at setting the strategic direction for global companies. He brings experience across all company functions, including Commercial Leadership, R&D, Operations, Quality, Regulatory, Service, and Support. Doug earned his Bachelor of Arts in Pre-medicine Studies from Ohio Wesleyan University.

Nina Webster, CEO and Managing Director, Dimerix

Nina has over thirty years of experience in the pharmaceutical industry, with leadership roles in investor relations, business development, and prosecution of intellectual property matters, as well as leading and managing the strategic, scientific and operational aspects of product development. Nina was formerly the Commercial Director for Acrux Limited (ASX: ACR), an Australian drug pharmaceutical company that has successfully developed and commercialised multiple products globally. Prior to Acrux, Nina was Director of Commercialisation and Intellectual Property for Immuron Limited (ASX: IMC), and previously spent 6 years in new product development with Wyeth Pharmaceuticals in the UK. Nina is also the Non-Executive Chairperson for SYNthesis BioVentures and a Non-Executive Director for Linear Clinical Research Limited. Nina holds a Ph.D in Pharmaceutics from Cardiff University, a Bachelor degree in Pharmacology, a Masters degree in Intellectual Property Law from Melbourne University and an Executive MBA from RMIT.